Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

Purpose: Uterine sarcomas are rare and heterogeneous tumors characterized by an aggressive clinical behavior. Their high rates of recurrence and mortality point to the urgent need for novel targeted therapies and alternative treatment strategies. However, no molecular prognostic or predictive biomarkers are available so far to guide choice and modality of treatment. Experimental Design: We investigated the expression of several druggable targets (phospho-S6S240 ribosomal protein, PTEN, PDGFR-α, ERBB2, and EGFR) in a large cohort of human uterine sarcoma samples (288), including leiomyosarcomas, low-grade and high-grade endometrial stromal sarcomas, undifferentiated uterine sarcomas, and adenosarcomas, together with 15 smooth muscle tumors of uncertain malignant potential (STUMP), 52 benign uterine stromal tumors, and 41 normal uterine tissues. The potential therapeutic value of the most promising target, p-S6S240, was tested in patient-derived xenograft (PDX) leiomyosarcoma models. Results: In uterine sarcomas and STUMPs, S6S240 phosphorylation (reflecting mTOR pathway activation) was associated with higher grade (P = 0.001) and recurrence (P = 0.019), as shown by logistic regression. In addition, p-S6S240 correlated with shorter progression-free survival (P = 0.034). Treatment with a dual PI3K/mTOR inhibitor significantly reduced tumor growth in 4 of 5 leiomyosarcoma PDX models (with tumor shrinkage in 2 models). Remarkably, the 4 responding models showed basal p-S6S240 expression, whereas the nonresponding model was scored as negative, suggesting a role for p-S6S240 in response prediction to PI3K/mTOR inhibition. Conclusions: Dual PI3K/mTOR inhibition represents an effective therapeutic strategy in uterine leiomyosarcoma, and p-S6S240 expression is a potential predictive biomarker for response to treatment. Clin Cancer Res; 23(5); 1274–85. ©2017 AACR.

[1]  L. Gorunova,et al.  Cytogenetic and molecular profile of endometrial stromal sarcoma , 2016, Genes, chromosomes & cancer.

[2]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[3]  F. Cognetti,et al.  First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? , 2016, Journal of Experimental & Clinical Cancer Research.

[4]  R. Motzer,et al.  A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma , 2016, The oncologist.

[5]  Su Jin Lee,et al.  BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells , 2016, Translational oncology.

[6]  P. Boutros,et al.  PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma , 2016, Journal of Translational Medicine.

[7]  N. Peeters,et al.  Uterine smooth muscle tumors of uncertain malignant potential: analysis of diagnoses and therapies illustrated by two case reports. , 2016, European journal of gynaecological oncology.

[8]  C. Galmarini,et al.  Unique features of trabectedin mechanism of action , 2016, Cancer Chemotherapy and Pharmacology.

[9]  F. Amant,et al.  Potential Therapeutic Targets in Uterine Sarcomas , 2015, Sarcoma.

[10]  Trevor Hastie,et al.  Clinically Relevant Molecular Subtypes in Leiomyosarcoma , 2015, Clinical Cancer Research.

[11]  S. Millis,et al.  Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets , 2015, Oncotarget.

[12]  Jian Xian,et al.  Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier , 2014, Genome Biology.

[13]  D. Bell,et al.  High-grade Endometrial Stromal Sarcomas: A Clinicopathologic Study of a Group of Tumors With Heterogenous Morphologic and Genetic Features , 2014, The American journal of surgical pathology.

[14]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[15]  E. Oliva,et al.  Tumours of the uterine corpus: Mesenchymal tumours , 2014 .

[16]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[17]  N. Yaegashi,et al.  Curcumin targets the AKT–mTOR pathway for uterine leiomyosarcoma tumor growth suppression , 2014, International Journal of Clinical Oncology.

[18]  C. Heldin,et al.  Targeting the PDGF signaling pathway in tumor treatment , 2013, Cell Communication and Signaling.

[19]  A. Misra,et al.  Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. , 2013, Biomaterials.

[20]  M. Powell,et al.  Management of sarcomas of the uterus , 2013, Current opinion in oncology.

[21]  J. Blay,et al.  Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. B. Hassan,et al.  Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy , 2013, Clinical Cancer Research.

[23]  F. Guyon,et al.  YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations , 2013, Modern Pathology.

[24]  M. van de Rijn,et al.  Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement , 2012, The American journal of surgical pathology.

[25]  K. Hunt,et al.  Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma , 2012, Clinical Cancer Research.

[26]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[27]  Jeffrey K. Mito,et al.  Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma , 2012, Sarcoma.

[28]  Y. Iwamoto,et al.  The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas , 2012, Cancer.

[29]  M. Khurshid,et al.  Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization , 2012, Journal of Cancer Research and Clinical Oncology.

[30]  Steven J. M. Jones,et al.  14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma , 2012, Proceedings of the National Academy of Sciences.

[31]  D. Ettinger,et al.  A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas , 2011, Cancer.

[32]  T. Clackson,et al.  Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens , 2011, Molecular Cancer Therapeutics.

[33]  N. Wake,et al.  Coincident expression of β-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas , 2010, Modern Pathology.

[34]  P. Lollini,et al.  NVP-BEZ235 as a New Therapeutic Option for Sarcomas , 2010, Clinical Cancer Research.

[35]  D. Timmerman,et al.  Clinical management of uterine sarcomas. , 2009, The Lancet. Oncology.

[36]  G. Kristiansen,et al.  Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[38]  Giovanni Parmigiani,et al.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.

[39]  J. Nesland,et al.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients , 2009, Histopathology.

[40]  M. Kalender,et al.  Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma , 2009, Cancer Chemotherapy and Pharmacology.

[41]  R. Lackman,et al.  Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy , 2008, Modern Pathology.

[42]  P. Pandolfi,et al.  The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.

[43]  L. Helman,et al.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.

[44]  C. Livasy,et al.  EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. , 2006, Gynecologic oncology.

[45]  I. Vergote,et al.  ERBB-2 gene overexpression and amplification in uterine sarcomas. , 2004, Gynecologic oncology.

[46]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[47]  Stefano Fumagalli,et al.  S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.

[48]  S. Yoshida,et al.  Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. , 2003, Endocrine-related cancer.

[49]  D Barnes,et al.  Immunohistochemical detection of steroid receptors in breast cancer: a working protocol , 2000, Journal of clinical pathology.

[50]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Gown,et al.  The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. , 1996, Gynecologic oncology.

[52]  W. Andersen,et al.  Uterine Smooth‐Muscle Tumors of Uncertain Malignant Potential , 1994, Obstetrics and gynecology.